Objective: There are limited models available to predict the linkages of musculoskeletal work (MSDS) among semiconductor back-end workers. This study seeks to overcome the gap through the development of predictive models for this specific population. Methods: Potential MSDS Risk Factors Extracted from 277 Ergonomic Investigation Reports for Work Compensation Claims conducted between 2011 – 2019.

Binary logistic regression approach is used to determine the predictor of extracted data. Result: significant predictor (p <0.05) includes poor posture (or = 1.822; 95% CI [1,261,2,632]), strong activity (or = 1.741; 95% CI [1,281,2,367)), static posture ( or = 1,796); 95% CI [1,367,2,378]), the appointment (or = 1.438; 95% CI [0.966,1,880]), transferred (or = 1.533; 95% CI [1,101,136]), push-pull (or = 0.990; 95% CI [0.744,1,317])), fix (or = 0.845; 95% CI [0.616,1,159]), preventive maintenance (or = 1,061; 95% CI [0.765,1,471]) and quality inspection (or = 0.982; 95% CI [0.729,1,322]).

Personal factors and labor duration also play an important role in this prediction model. The accuracy of the model carried out through cross validation with 30 new data sets is 86.2%. Face validation activities among 30 experts show promising results, with a score of the average agreement on predictor inclusion which will be assessed at 7.9 / 10 (SD = 1.9). Conclusion: This model allows practitioners to predict the potential of MSD cases among semiconductor back-end workers, and proactively plan the right mitigation measures.

Data collection in multiple sclerosis: MSDS Approach

Multiple Sclerosis (MS) is a chronic inflammatory disease that often occurs in the central nervous system that affects patients for decades. As MS monitoring and treatment becomes more personalized and complex, assessment and collection of different parameters ranging from clinical assessment through laboratories and imaging data to data reported by patients becomes increasingly important for innovative patient management in MS. These aspects are predestin electronic data processing for use in MS documentation.

Such technology allows fast health information exchange between patients, practitioners, and caregivers, regardless of time and location. In this paper perspective, we present our digital strategy from Dresden, where we are developing multiple sclerosis Documentation System (MSDS) into the EHEALTH platform that can be used for various purposes. Various use cases are presented that apply this software platform and offer an important perspective for the management of innovative digital patients in the future. MS holistic patient management, electronically supported by clinical lines, will have an important impact on other patient care fields, such as neurorehabilitation.

RAMP package for MSD risk management in handling manuals – tools that can be accessed freely, with website and training courses.

In this paper, the ramp package is served with the aim of facilitating the application of ramp tools to systematically manage MSD risk. This package consists of ramp tools (risk assessment and management tool for proactively handling manuals), websites ramp, and free, globally available, training courses (MOOCs). The module of action used to manage the identified MSD risk is introduced. This tool, which includes various risks, applies to the entire risk management process.

Next, the ramp is open openly for download, and free to use. Ramp tools and training materials are developed using participatory iterative methodologies including researchers and practitioners. Ramp is downloaded in 86 countries in the first 26 months since it was launched and more than 2400 students from high and low income countries have joined the MOOC. RAMP packages meet the needs of organizations for risk assessment tools and comprehensive risk management.

The prevalence of MSDS and risk assessment of posture on the floor mopping activities through subjective and objective steps.

Housing and commercial cleaning is part of our daily routine to maintain sanitation around the environment. Professional health care involved in such cleaning activities has been a major concern throughout the world. This study investigated the risk of musculoskeletal disorders in professional cleaners involved in mopping floor assignments. Cross-sectional studies were carried out on 132 professional mopping using the modified Nordic questionnaire. Pearson correlation tests are implemented to study the relationship of pain felt by work experience. Muscle strains and postural risks are evaluated using three-channel electromyography and real-time movement taking each of 15 professionals during the mopping floor.

Regarding musculoskeletal injury, the risk reported in the majority in the right hand, lower back, left wrist, right shoulder, left biceps, and worker’s right wrist. Work experience has a low negative relationship with MSDS on the left wrist, right wrist, right elbow, lower back, and right arm (P <0.01). The EMG surface shows the occurrence of higher muscle activity in the muscle of trapezius and biceps brisachi (BB) over and the muscles of flexor carpi are dominant and the BB muscles from the hands that are not dominant at the top and bottom of the mop stem, respectively.

The relationship between the body mass index and pain intensity among veterans with musculoskeletal disorders: findings from the MSD cohort study.

To check the relationship between the body mass index (BMI) and the intensity of pain among veterans with the diagnosis of musculoskeletal disorders (MSDS; nontraumatic joints; osteoarthritis; lower back pain, back, and neck). Veteran Health Record Data (VHA). The national cohort of US military veterans with MSDS in VHA CARE during 2001-2012 (n = 1,759,338). These cross-sectional data were analyzed using the negative binomial model of pain intensity as a BMI function, adjusted to comorbidity. and demographics.

Samples have an average age of 59.4, 95% are men, 77% white / non-Hispanic, 79% overweight or obese, and 42% report no pain in the diagnosis of the MSD index. Overall, there is a J-shaped relationship between BMI and pain (Nadir = 27 kg / m2), with severe obesity (BMI ≥ 40 kg / m2) most likely to report pain (or vs. normal weight = 1.23, 95% interval trust = 1.21-1.26).

Goat Anti-Mouse IgG(H+L) Alexa Fluor 594–conjugated
S0005	Affbiotech	200ul	EUR 376

Goat Anti-Rabbit IgG(H+L) Alexa Fluor 594–conjugated
S0006	Affbiotech	200ul	EUR 376

Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated
Ab8011-001	GenDepot	1mg	EUR 334

Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594)
43R-ID012AF	Fitzgerald	300 ug	EUR 410
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594)

SAM FCM (Alexa Fluor 647)
abx098902-100tests	Abbexa	100 tests	EUR 1233

SAM FCM (Alexa Fluor 488)
abx098904-60tests	Abbexa	60 tests	EUR 1358

EGFR antibody (Alexa Fluor 488)
61R-E109BAF	Fitzgerald	125 ug	EUR 706
Description: Mouse monoclonal EGFR antibody (Alexa Fluor 488)

Anti-RPSA Alexa Fluor® 488
A4-829-C100	ExBio	0.1 mg	EUR 310

Anti-CD40 antibody (Alexa-fluor 488)
STJ170000	St John's Laboratory	100 µg	EUR 393
Description: CD40 (48 to 50 kDa) is a transmembrane glycoprotein mainly expressed on the surface of B cells and also expressed on monocytes, dendritic cells, and thymic epithelium. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the low affinity nerve growth factor (NGF) receptor and CD95/Fas. CD40 is the receptor for CD40 ligand. CD40L (CD40L, CD154, gp39, and TRAM) belongs to the TNF gene family and is expressed more widely than CD40, predominantly on activated CD4+ T cells. Following interaction with CD40 ligand, CD40 mediates a number of major immunoregulatory functions, central to the control of thymus dependent humoral immunity and may be critical in the development of cell mediated immune responses. Other biological actions include B cell homotypic adhesion, proliferation, immunoglobulin isotype switch, and secretion. Activation of CD40 has also been shown to inhibit the growth of certain B cell lymphomas and to induce the death of transformed cells of mesenchymal or epithelial origin

Anti-LAMP3 antibody (Alexa-fluor 488)
STJ170004	St John's Laboratory	100 µg	EUR 393
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface.

Anti-LAMP3 antibody (Alexa-fluor 546)
STJ170005	St John's Laboratory	100 µg	EUR 393
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface.

Anti-LAMP3 antibody (Alexa-fluor 647)
STJ170006	St John's Laboratory	100 µg	EUR 393
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface.

Anti-IL3RA antibody (Alexa-fluor 488)
STJ170009	St John's Laboratory	100 µg	EUR 393
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment

Anti-IL3RA antibody (Alexa-fluor 546)
STJ170010	St John's Laboratory	100 µg	EUR 393
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment

Anti-IL3RA antibody (Alexa-fluor 647)
STJ170011	St John's Laboratory	100 µg	EUR 393
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment

Anti-CD207 antibody (Alexa-fluor 488)
STJ170014	St John's Laboratory	100 µg	EUR 393
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307)

Anti-CD207 antibody (Alexa-fluor 546)
STJ170015	St John's Laboratory	100 µg	EUR 393
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307)

Anti-CD207 antibody (Alexa-fluor 647)
STJ170016	St John's Laboratory	100 µg	EUR 393
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307)

Anti-IL7R antibody (Alexa-fluor 488)
STJ170020	St John's Laboratory	100 µg	EUR 393
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54)

Anti-IL7R antibody (Alexa-fluor 546)
STJ170021	St John's Laboratory	100 µg	EUR 393
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54)

Anti-IL7R antibody (Alexa-fluor 647)
STJ170022	St John's Laboratory	100 µg	EUR 393
Description: The IL7-R consists of 2 chains, IL-7R known as CD127 and common cytokine receptor chain known as CD132. A 75 to 80kDa human IL-7 receptor has been cloned that belongs to hematopoietic cytokinereceptor super family. R34-34, raised against human leukemic pre-B cells, recognized a molecule expressed on normal B cell precursors but not on mature B cells. This antibody specifically reverted IL-7 mediated growth inhibition of leukemic BCP (normal B cells precursors) and mature T cells. IL-7R expression is dramatically influenced by cytokines and antigens. This IL-7R displays both high and low affinity for its ligand (IL-7). Inhibitory and proliferative effects of IL-7 can be mediated through the same receptor on various lineages. CD4+ memory T cells express high level of IL-7R Subsets that express it generally require it, including progenitors of T and B cells, naïve and memory T cells. (Pandrau-Garcia D et al, 1994, Blood, 83, 3613-9 Mazzucchelli R et al, Nat. Review Immunol., 2007,7, 144-54)

Anti-Hu CD16 Alexa Fluor® 488
A4-646-T100	ExBio	100 tests	EUR 269

Goat anti Mouse IgG1 (Alexa Fluor 488)
43R-1649	Fitzgerald	500 ug	EUR 570
Description: Goat anti Mouse IgG1 secondary antibody (Alexa Fluor 488)

Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG)
50337	Alpha Diagnostics	0.5 ml	EUR 225

Alpha Fluor™ 594 C5 Maleimide
1891	AAT Bioquest	1 mg	EUR 219

Streptavidin-Alexa594 (Alexas fluor 594) conjugate
SV-A594-100	Alpha Diagnostics	100 tests	EUR 225

Alpha Fluor™ 532 acid [equivalent to Alexa Fluor™ 532 acid]
1795	AAT Bioquest	10 mg	EUR 393

Anti-Hu CD72 Alexa Fluor® 488
A4-310-T100	ExBio	100 tests	EUR 269

Anti-Bov CD9 Alexa Fluor® 488
A4-354-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD30 Alexa Fluor® 700
A7-455-T100	ExBio	100 tests	EUR 269

Anti-Hu CD94 Alexa Fluor® 700
A7-727-T100	ExBio	100 tests	EUR 269

Anti-Hu CD56 Alexa Fluor® 700
A7-789-T100	ExBio	100 tests	EUR 269

AF350-streptavidin conjugate [Streptavidin, Alexa Fluor™ 350 Conjugate]
16890	AAT Bioquest	1 mg	EUR 176

AF488-streptavidin conjugate [Streptavidin, Alexa Fluor™ 488 Conjugate]
16891	AAT Bioquest	1 mg	EUR 176

AF350 Phalloidin [equivalent to Alexa Fluor® 350 phalloidin]
23150	AAT Bioquest	300 Tests	EUR 306

AF488 Phalloidin [equivalent to Alexa Fluor® 488 phalloidin]
23153	AAT Bioquest	300 Tests	EUR 306

Donkey anti Goat IgG (H + L) (Alexa Fluor 647)
43R-ID028AF	Fitzgerald	500 ug	EUR 430
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 647)

Donkey anti Chicken IgY (H + L) (Alexa Fluor 647)
43R-ID060AF	Fitzgerald	300 ug	EUR 425
Description: Donkey anti Chicken IgY (H + L) (Fab'2) (Alexa Fluor 647)

Goat Anti-Rabbit IgG(H+L) Alexa Fluor 647–conjugated
S0013	Affbiotech	200ul	EUR 304

Goat Anti-Mouse IgG(H+L) Alexa Fluor 647–conjugated
S0014	Affbiotech	200ul	EUR 304

Goat Anti-Mouse IgG(H+L) Alexa Fluor 488–conjugated
S0017	Affbiotech	200ul	EUR 304

Goat Anti-Rabbit IgG(H+L) Alexa Fluor 488–conjugated
S0018	Affbiotech	200ul	EUR 304

Anti-Hu CD3 zeta (pY153) Alexa Fluor® 488
A4-686-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY72) Alexa Fluor® 488
A4-712-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY142) Alexa Fluor® 488
A4-730-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY111) Alexa Fluor® 488
A4-737-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY153) Alexa Fluor® 647
A6-686-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY72) Alexa Fluor® 647
A6-712-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY142) Alexa Fluor® 647
A6-730-C100	ExBio	0.1 mg	EUR 269

Anti-Hu CD3 zeta (pY111) Alexa Fluor® 647
A6-737-C100	ExBio	0.1 mg	EUR 269

Donkey Anti-Rabbit IgG (H+L), Alexa Fluor® 488 Conjugated
Ab8032-001	GenDepot	0.5mg	EUR 435

Anti-LAMP3 (human) Monoclonal Antibody (104G4) (Alexa Fluor® 488)
M09406	BosterBio	100ug	EUR 565
Description: Mouse Monoclonal LAMP3 (human) Antibody (104G4) (Alexa Fluor® 488). Validated in IHC and tested in Human.

Anti-Langerin (human) Monoclonal Antibody (DCGM4/122D5) (Alexa Fluor® 488)
M02316	BosterBio	100ug	EUR 580
Description: Mouse Monoclonal Langerin (human) Antibody (DCGM4/122D5) (Alexa Fluor® 488). Validated in IHC and tested in Human.

Rabbit Anti-Rat IgG (H+L)-Alexa 488 Fluor conjugate (adsorbed with human IgG)
50336	Alpha Diagnostics	0.5 ml	EUR 225

Recombinant (E.Coli) Human Thyrostimulin Beta
RP-594	Alpha Diagnostics	10 ug	EUR 286

PDL1 Recombinant Protein
96-594	ProSci	0.1 mg	EUR 595.25
Description: Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

FGF2 Recombinant Protein
91-594	ProSci	0.05 mg	EUR 542.75
Description: Fibroblast growth factor 2(FGF2) is a secreted protein and belongs to the heparin-binding growth factors family. FGF2 is produced by epithelial, tumor and other cell types. It involved in developmental processes and regulates differentiation, proliferation, and migration, FGF2 is a critical factor for growing embryonic stem cells in culture without inducing differentiation. FGF2 has a high affinity for heparan sulfate and binding is a step in the FGF basic activation of FGFR tyrosine kinase.

CD83 Recombinant Protein
92-594	ProSci	0.05 mg	EUR 401
Description: CD83 antigen is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. CD83 is expressed by activated lymphocytes, Langerhans cells and interdigitating reticulum cells. It contains one Ig-like V-type (immunoglobulin-like) domain, the soluble CD83 has the opposite effect and has an immune inhibitory capacity. Due to its immune inhibitory function, CD83 may play a significant role in antigen presentation or the cellular interactions that follow lymphocyte activation.

BBT-594
B2114-25	Biovision		EUR 631

BBT-594
B2114-5	Biovision		EUR 196

Alpha Fluor™ 488 amine
1705	AAT Bioquest	1 mg	EUR 306

Alpha Fluor™ 488 Hydroxylamine
1900	AAT Bioquest	1 mg	EUR 306

Tide Fluor 2-LL-37
H-8286.0100	Bachem	0.1mg	EUR 312
Description: Sum Formula: C205H340N60O53+dye

Tide Fluor 2-LL-37
H-8286.0500	Bachem	0.5mg	EUR 1017
Description: Sum Formula: C205H340N60O53+dye

Anti-Cytokeratins Alexa Fluor488
A4-108-C025	ExBio	0.025 mg	EUR 175

Anti-Cytokeratins Alexa Fluor488
A4-108-C100	ExBio	0.1 mg	EUR 310

Anti-PSMA Alexa Fluor488
A4-539-C025	ExBio	0.025 mg	EUR 227

Anti-PSMA Alexa Fluor488
A4-539-C100	ExBio	0.1 mg	EUR 414

Anti-FoxP3 Alexa Fluor488
A4-601-C025	ExBio	0.025 mg	EUR 201

Anti-FoxP3 Alexa Fluor488
A4-601-C100	ExBio	0.1 mg	EUR 362

Anti-Phosphotyrosine Alexa Fluor647
A6-263-C025	ExBio	0.025 mg	EUR 154

Anti-Phosphotyrosine Alexa Fluor647
A6-263-C100	ExBio	0.1 mg	EUR 269

Anti-LCK Alexa Fluor647
A6-269-C025	ExBio	0.025 mg	EUR 206

Anti-LCK Alexa Fluor647
A6-269-C100	ExBio	0.1 mg	EUR 373

Anti-FoxP3 Alexa Fluor647
A6-601-C025	ExBio	0.025 mg	EUR 201

Anti-FoxP3 Alexa Fluor647
A6-601-C100	ExBio	0.1 mg	EUR 362

Alpha Fluor™ 488 NHS Ester
1812	AAT Bioquest	1 mg	EUR 219

Alpha Fluor™ 532 NHS Ester
1819	AAT Bioquest	1 mg	EUR 219

Metal Fluor™ Zn-520, AM
21263	AAT Bioquest	1 mg	EUR 219

Helix Fluor™ 6-JOE Phosphoramidite
6046	AAT Bioquest	100 umoles	EUR 50

Streptavidin-Alexa488 (Alexas fluor 488) conjugate
SV-A488-100	Alpha Diagnostics	100 tests	EUR 225

Tide Fluor 2-LL-37 (scrambled)
H-8288.0100	Bachem	0.1mg	EUR 312
Description: Sum Formula: C205H340N60O53+dye

Tide Fluor 2-LL-37 (scrambled)
H-8288.0500	Bachem	0.5mg	EUR 1017
Description: Sum Formula: C205H340N60O53+dye

Tide Fluor 5WS-o-Conotoxin GVIA
H-8356.0100	Bachem	0.1mg	EUR 1146
Description: Sum Formula: C120H182N38O43S6+dye

Anti-Cytokeratin 18 Alexa Fluor488
A4-106-C025	ExBio	0.025 mg	EUR 186

Anti-Cytokeratin 18 Alexa Fluor488
A4-106-C100	ExBio	0.1 mg	EUR 331

Anti-Cytokeratin 19 Alexa Fluor488
A4-120-C025	ExBio	0.025 mg	EUR 186

Anti-Cytokeratin 19 Alexa Fluor488
A4-120-C100	ExBio	0.1 mg	EUR 331

Anti-Ki-67 Alexa Fluor488
A4-155-T025	ExBio	25 tests	EUR 154

Anti-Ki-67 Alexa Fluor488
A4-155-T100	ExBio	100 tests	EUR 269

Anti-Hu CD45 Alexa Fluor488
A4-160-T100	ExBio	100 tests	EUR 269

Anti-Hu CD193 Alexa Fluor488
A4-161-T100	ExBio	100 tests	EUR 269

The relationship between BMI and pain varies by MSD, with a stronger relationship in the osteoarthritis group and a less clear relationship in the back and lower back pain group. There is a high prevalence of overweight / obesity among veterans with MSD. The high level of BMI (> 27 kg / m2) is associated with an increase in pain opportunities, the most obvious among veterans with osteoarthritis.